| 1 | Characterization of virus‒host recombinant variants of the hepatitis E virus | 3.7 | 7 | Citations (PDF) |
| 2 | Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation | 2.9 | 9 | Citations (PDF) |
| 3 | Low to undetectable Omicron BQ.1.1 neutralization by patient’s sera a month after initiation of AZD7442 600 mg | 2.9 | 7 | Citations (PDF) |
| 4 | Clustered Cases of Waterborne Hepatitis E Virus Infection, France | 3.3 | 14 | Citations (PDF) |
| 5 | SARS-CoV-2 Co-Infections and Recombinations Identified by Long-Read Single-Molecule Real-Time Sequencing | 3.7 | 10 | Citations (PDF) |
| 6 | Molecular evolution of omicron variant in immunocompromised individuals with chronic SARS-CoV-2 infection | 2.9 | 2 | Citations (PDF) |
| 7 | Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients | 4.6 | 124 | Citations (PDF) |
| 8 | Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | 5.4 | 14 | Citations (PDF) |
| 9 | Antibody titers and protection against a SARS-CoV-2 infection | 2.9 | 107 | Citations (PDF) |
| 10 | Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies | 5.5 | 30 | Citations (PDF) |
| 11 | Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Kinetics and Protection Duration | 5.4 | 14 | Citations (PDF) |
| 12 | Vectorial Release of Human RNA Viruses from Epithelial Cells | 3.3 | 3 | Citations (PDF) |
| 13 | Antibody titers and breakthrough infections with Omicron SARS-CoV-2 | 2.9 | 33 | Citations (PDF) |
| 14 | Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load | 3.3 | 14 | Citations (PDF) |
| 15 | Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies | 0.8 | 7 | Citations (PDF) |
| 16 | Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine | 3.0 | 10 | Citations (PDF) |
| 17 | Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants | 2.9 | 6 | Citations (PDF) |
| 18 | Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response | 2.8 | 18 | Citations (PDF) |
| 19 | Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients | 1.7 | 28 | Citations (PDF) |
| 20 | Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response | 2.9 | 6 | Citations (PDF) |
| 21 | Persistence of hepatitis E virus in the cerebrospinal fluid despite apparently successful ribavirin therapy | 3.2 | 5 | Citations (PDF) |
| 22 | Diagnostic Performance of an Automated System for Assaying Anti-Hepatitis E Virus Immunoglobulins M and G Compared with a Conventional Microplate Assay | 3.3 | 10 | Citations (PDF) |
| 23 | Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant | 3.7 | 7 | Citations (PDF) |
| 24 | Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients? | 3.3 | 1 | Citations (PDF) |
| 25 | Human Cytomegalovirus Modifies Placental Small Extracellular Vesicle Composition to Enhance Infection of Fetal Neural Cells In Vitro | 3.3 | 8 | Citations (PDF) |
| 26 | Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population | 2.9 | 7 | Citations (PDF) |
| 27 | Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection | 3.0 | 40 | Citations (PDF) |
| 28 | Omicron Wave SARS-CoV-2 Diagnosis: Evaluation of Saliva, Anterior Nasal, and Nasopharyngeal Swab Samples | 3.7 | 15 | Citations (PDF) |
| 29 | Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model | 4.5 | 21 | Citations (PDF) |
| 30 | Quantifying the impact of public health protection measures on the spread of SARS-CoV-2 | 2.9 | 5 | Citations (PDF) |
| 31 | Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France | 2.9 | 15 | Citations (PDF) |
| 32 | Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection | 2.1 | 8 | Citations (PDF) |
| 33 | Classification of the Zoonotic Hepatitis E Virus Genotype 3 Into Distinct Subgenotypes | 3.9 | 44 | Citations (PDF) |
| 34 | An Evaluation of Hepatitis E Virus Molecular Typing Methods | 1.1 | 10 | Citations (PDF) |
| 35 | Effector memory CD8 T cell response elicits Hepatitis E Virus genotype 3 pathogenesis in the elderly | 4.4 | 25 | Citations (PDF) |
| 36 | Estimating the impact of public health strategies on the spread of SARS‐CoV‐2: Epidemiological modelling for Toulouse, France | 7.0 | 7 | Citations (PDF) |
| 37 | Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis | 4.4 | 15 | Citations (PDF) |
| 38 | Réplication du virus de l’hépatite E dans les cellules intestinales | 0.2 | 0 | Citations (PDF) |
| 39 | Analyses of Clinical and Biological Data for French and Belgian Immunocompetent Patients Infected With Hepatitis E Virus Genotypes 4 and 3 | 3.9 | 9 | Citations (PDF) |
| 40 | Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2 | 3.3 | 7 | Citations (PDF) |
| 41 | Side effect of a 6 p.m curfew for preventing the spread of SARS-CoV-2: A modeling study from Toulouse, France | 2.9 | 9 | Citations (PDF) |
| 42 | Influence of age on the spread of SARS-CoV-2 variant B.1.1.7 | 3.1 | 4 | Citations (PDF) |
| 43 | Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment | 3.3 | 138 | Citations (PDF) |
| 44 | Rat Hepatitis E Virus: Presence in Humans in South-Western France? | 2.6 | 18 | Citations (PDF) |
| 45 | One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection | 2.9 | 7 | Citations (PDF) |
| 46 | Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation | 5.0 | 7 | Citations (PDF) |
| 47 | Mobilization of γδ T Cells and IL-10 Production at the Acute Phase of Hepatitis E Virus Infection in Cytomegalovirus Carriers | 0.6 | 9 | Citations (PDF) |
| 48 | Hepatitis E Virus Quasispecies in Cerebrospinal Fluid with Neurological Manifestations | 3.0 | 17 | Citations (PDF) |
| 49 | Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant | 6.8 | 113 | Citations (PDF) |
| 50 | Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays | 3.7 | 24 | Citations (PDF) |
| 51 | Prediction of SARS-CoV-2 Variant Lineages Using the S1-Encoding Region Sequence Obtained by PacBio Single-Molecule Real-Time Sequencing | 3.3 | 13 | Citations (PDF) |
| 52 | Hepatitis E Virus Infection: Neurological Manifestations and Pathophysiology | 3.1 | 25 | Citations (PDF) |
| 53 | THETA: a new genotypic approach for predicting HIV-1 CRF02-AG coreceptor usage | 4.8 | 4 | Citations (PDF) |
| 54 | Hepatitis E virus replication in human intestinal cells | 21.2 | 88 | Citations (PDF) |
| 55 | Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA | 1.7 | 30 | Citations (PDF) |
| 56 | Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study | 5.4 | 100 | Citations (PDF) |
| 57 | Performance evaluation of the Vela Dx Sentosa next-generation sequencing system for HIV-1 DNA genotypic resistance | 3.1 | 21 | Citations (PDF) |
| 58 | Risk for Hepatitis E Virus Transmission by Solvent/Detergent–Treated Plasma | 3.9 | 14 | Citations (PDF) |
| 59 | Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection | 10.4 | 10 | Citations (PDF) |
| 60 | Hepatitis E Virus: How It Escapes Host Innate Immunity | 3.0 | 20 | Citations (PDF) |
| 61 | No evidence of sexual transmission of HEV among individuals using HIV pre‐exposure prophylaxis | 2.1 | 15 | Citations (PDF) |
| 62 | Evaluation of the Aptima™ transcription-mediated amplification assay (Hologic®) for detecting SARS-CoV-2 in clinical specimens | 3.1 | 36 | Citations (PDF) |
| 63 | Insertions and Duplications in the Polyproline Region of the Hepatitis E Virus | 3.9 | 658 | Citations (PDF) |
| 64 | Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections | 2.6 | 111 | Citations (PDF) |
| 65 | Optimized Hepatitis E Virus (HEV) Culture and Its Application to Measurements of HEV Infectivity | 3.3 | 28 | Citations (PDF) |
| 66 | The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France | 2.9 | 23 | Citations (PDF) |
| 67 | Update: proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus A) | 3.3 | 330 | Citations (PDF) |
| 68 | Seroprevalence of hepatitis E virus among blood donors on Corsica, France, 2017 | 5.0 | 13 | Citations (PDF) |
| 69 | Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin | 3.3 | 10 | Citations (PDF) |
| 70 | Hepatitis E virus infections in Europe | 3.1 | 71 | Citations (PDF) |
| 71 | Failure to respond to ribavirin despite elevated intra‐erythrocyte zinc level in transplant‐patients with chronic hepatitis E virus infection | 2.2 | 9 | Citations (PDF) |
| 72 | Performance characteristics of the VIDAS® ANTI-HEV IgM and IgG assays | 3.1 | 17 | Citations (PDF) |
| 73 | Multirecombinant Enterovirus A71 Subgenogroup C1 Isolates Associated with Neurologic Disease, France, 2016–2017 | 3.9 | 25 | Citations (PDF) |
| 74 | Transfusion-Transmitted Hepatitis E Virus Infection in France | 1.6 | 62 | Citations (PDF) |
| 75 | Hepatitis E Virus Infections among Patients with Acute Febrile Jaundice in Burkina Faso | 3.3 | 12 | Citations (PDF) |
| 76 | Viral load and clinical manifestations of hepatitis E virus genotype 3 infections | 2.1 | 15 | Citations (PDF) |
| 77 | Screening, diagnosis and risks associated with Hepatitis E virus infection | 4.0 | 27 | Citations (PDF) |
| 78 | Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis | 3.8 | 22 | Citations (PDF) |
| 79 | Peripheral Plasma and Semen Cytokine Response to Zika Virus in Humans | 3.9 | 12 | Citations (PDF) |
| 80 | Should 12‐ or 24‐week post‐ribavirin follow‐up be considered to define sustained virological response in transplant patients treated for chronic hepatitis E virus infection? | 2.2 | 4 | Citations (PDF) |
| 81 | No evidence of occult hepatitis C or E virus infections in liver‐transplant patients with sustained virological response after therapy with direct acting agents | 2.2 | 5 | Citations (PDF) |
| 82 | The Prevalence of Hepatitis E in a Patient Cohort Presenting With Addictive Injection Behavior | 2.6 | 4 | Citations (PDF) |
| 83 | Long-term evolution of transmitted CXCR4-using HIV-1 under effective antiretroviral therapyAids, 2019, 33, 1977-1985 | 2.5 | 2 | Citations (PDF) |
| 84 | Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen | 3.2 | 4 | Citations (PDF) |
| 85 | Vectorial Release of Hepatitis E Virus in Polarized Human Hepatocytes | 3.7 | 50 | Citations (PDF) |
| 86 | Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients | 2.9 | 41 | Citations (PDF) |
| 87 | Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients | 3.6 | 32 | Citations (PDF) |
| 88 | Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort | 2.1 | 4 | Citations (PDF) |
| 89 | Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial | 3.2 | 30 | Citations (PDF) |
| 90 | HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform | 3.2 | 30 | Citations (PDF) |
| 91 | A European multicenter study on the analytical performance of the VERIS HBV assay | 3.1 | 2 | Citations (PDF) |
| 92 | Transmission of Hepatitis E Virus With Plasma Exchange in Kidney Transplant Recipients | 1.2 | 17 | Citations (PDF) |
| 93 | Transmission and Epidemiology of Hepatitis E Virus Genotype 3 and 4 Infections | 6.7 | 88 | Citations (PDF) |
| 94 | Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein | 1.0 | 190 | Citations (PDF) |
| 95 | Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world | 3.6 | 9 | Citations (PDF) |
| 96 | Kinetics of anti-ZIKV antibodies after Zika infection using two commercial enzyme-linked immunoassays | 1.7 | 44 | Citations (PDF) |
| 97 | Should Persistent Hepatitis E Virus Replication in Transplant Patients Be Tolerated? | 1.2 | 1 | Citations (PDF) |
| 98 | Monitoring human enteric viruses in wastewater and relevance to infections encountered in the clinical setting: a one-year experiment in central France, 2014 to 2015 | 5.0 | 144 | Citations (PDF) |
| 99 | Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface | 13.9 | 115 | Citations (PDF) |
| 100 | Hepatitis E prevalence in French Polynesian blood donors | 2.4 | 9 | Citations (PDF) |
| 101 | CCR5 structural plasticity shapes HIV-1 phenotypic properties | 4.4 | 32 | Citations (PDF) |
| 102 | Performance of a commercial assay for detecting and quantifying HEV RNA in faeces | 3.1 | 7 | Citations (PDF) |
| 103 | Accurate quantification of CXCR4-using HIV-1 variants by Illumina deep-sequencingAids, 2018, 32, 2429-2431 | 2.5 | 1 | Citations (PDF) |
| 104 | Hepatitis E virus–associated cryoglobulinemia in solid‐organ–transplant recipients | 4.1 | 33 | Citations (PDF) |
| 105 | Impact of donor BK polyomavirus replication on recipient infections in living donor transplantation | 2.2 | 20 | Citations (PDF) |
| 106 | Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies | 5.4 | 5 | Citations (PDF) |
| 107 | Diversity of hepatitis E virus genotype 3 | 7.0 | 43 | Citations (PDF) |
| 108 | Detection of Zika, dengue and chikungunya viruses using single-reaction multiplex real-time RT-PCR | 1.7 | 29 | Citations (PDF) |
| 109 | A fully automated system using transcription-mediated amplification for the molecular diagnosis of hepatitis E virus in human blood and faeces | 3.1 | 8 | Citations (PDF) |
| 110 | Acute hepatitis E in French patients and neurological manifestations | 2.9 | 64 | Citations (PDF) |
| 111 | Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen | 5.4 | 20 | Citations (PDF) |
| 112 | Performance comparison of deep sequencing platforms for detecting HIV‐1 variants in the pol gene | 3.8 | 8 | Citations (PDF) |
| 113 | Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use | 3.5 | 11 | Citations (PDF) |
| 114 | A European multicentre study on the comparison of HCV viral loads between VERIS HCV assay and COBAS ® TaqMan ® HCV Test and RealTime HCV Assay | 3.1 | 5 | Citations (PDF) |
| 115 | Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma | 3.8 | 53 | Citations (PDF) |
| 116 | Evaluation of two VIDAS ® prototypes for detecting anti-HEV IgG | 3.1 | 9 | Citations (PDF) |
| 117 | Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver | 21.2 | 126 | Citations (PDF) |
| 118 | European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay | 4.1 | 6 | Citations (PDF) |
| 119 | Characterization of the lipid envelope of exosome encapsulated HEV particles protected from the immune response | 2.9 | 119 | Citations (PDF) |
| 120 | Malignancies in hepatitis C virus‐positive and ‐negative kidney transplant recipients: A case‐controlled study | 2.2 | 3 | Citations (PDF) |
| 121 | A European multicientre study on the comparison of HIV-1 viral loads between VERIS HIV-1 Assay and Roche COBAS® TAQMAN® HIV-1 test, Abbott RealTime HIV-1 Assay, and Siemens VERSANT HIV-1 Assay | 3.1 | 8 | Citations (PDF) |
| 122 | HEV infection in French HIV-infected patients | 2.9 | 31 | Citations (PDF) |
| 123 | Chronic hepatitis E virus infection in a cirrhotic patient | 1.3 | 19 | Citations (PDF) |
| 124 | Transfusion‐acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient | 2.2 | 15 | Citations (PDF) |
| 125 | A European multicientre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS ® TAQMAN ® HBV test, Abbott RealTime HBV assay, Siemens VERSANT HBV assay, and Qiagen artus HBV RG kit | 3.1 | 13 | Citations (PDF) |
| 126 | Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study | 3.6 | 91 | Citations (PDF) |
| 127 | Atypical hemolytic uremic syndrome triggered by varicella infection | 0.8 | 7 | Citations (PDF) |
| 128 | Clinical phenotype and outcome of hepatitis E virus–associated neuralgic amyotrophy | 1.0 | 88 | Citations (PDF) |
| 129 | Hepatitis E virus infection | 50.7 | 521 | Citations (PDF) |
| 130 | HEV and transfusion-recipient risk | 0.2 | 43 | Citations (PDF) |
| 131 | European Multicenter Study on Analytical Performance of Veris HIV-1 Assay | 4.1 | 2 | Citations (PDF) |
| 132 | Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring? | 2.5 | 3 | Citations (PDF) |
| 133 | Comparison of Cobas® HPV and Anyplex™ II HPV28 assays for detecting and genotyping human papillomavirus | 1.7 | 9 | Citations (PDF) |
| 134 | Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France | 3.9 | 29 | Citations (PDF) |
| 135 | Rabbit Hepatitis E Virus Infections in Humans, France | 3.9 | 164 | Citations (PDF) |
| 136 | Patterns of residual HIV-1 RNA shedding in the seminal plasma of patients on effective antiretroviral therapy | 1.7 | 13 | Citations (PDF) |
| 137 | Zika Virus Infection and Prolonged Viremia in Whole-Blood Specimens | 3.9 | 89 | Citations (PDF) |
| 138 | Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma | 2.4 | 2 | Citations (PDF) |
| 139 | L’hépatite E, une infection virale encore méconnue dans les pays industriels | 0.1 | 0 | Citations (PDF) |
| 140 | Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis | 3.3 | 42 | Citations (PDF) |
| 141 | Persistent But Not Replicating HIV-1 Cell-Associated DNA in Semen of Long-Term ART Experienced Men | 0.8 | 1 | Citations (PDF) |
| 142 | Hepatitis E Pathogenesis | 3.3 | 91 | Citations (PDF) |
| 143 | Quantification of HEV RNA by Droplet Digital PCR | 3.3 | 31 | Citations (PDF) |
| 144 | A Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance and Tropism Testing Using 454 Ultra Deep Pyrosequencing | 2.4 | 15 | Citations (PDF) |
| 145 | Brief Report: HIV-1 Tropism During Primary Infections in France: 1996–2014 | 1.8 | 5 | Citations (PDF) |
| 146 | Extrahepatic manifestations of hepatitis E virus | 4.1 | 110 | Citations (PDF) |
| 147 | Treatment of autochthonous acute hepatitis E with short‐term ribavirin: a multicenter retrospective study | 4.1 | 68 | Citations (PDF) |
| 148 | A 3-month course of ciprofloxacin does not prevent BK virus replication in heavily immunosuppressed kidney-transplant patients | 3.1 | 17 | Citations (PDF) |
| 149 | Detection of Hepatitis E Virus in Sewage After an Outbreak on a French Island | 2.6 | 60 | Citations (PDF) |
| 150 | Analytical performance of the VERIS MDx system HCV assay for detecting and quantifying HCV RNA | 3.1 | 8 | Citations (PDF) |
| 151 | Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients | 3.2 | 1 | Citations (PDF) |
| 152 | Hepatitis E | 1.1 | 51 | Citations (PDF) |
| 153 | Transmission of HCV NS5A Inhibitor–Resistant Variants Among HIV-Infected Men Who Have Sex With Men | 5.4 | 17 | Citations (PDF) |
| 154 | Characterization of the Specificity, Functionality, and Durability of Host T‐Cell Responses Against the Full‐Length Hepatitis E Virus | 10.6 | 47 | Citations (PDF) |
| 155 | ZIKA virus reveals broad tissue and cell tropism during the first trimester of pregnancy | 3.5 | 177 | Citations (PDF) |
| 156 | A nationwide survey of hepatitis E viral infection in French blood donors | 10.6 | 201 | Citations (PDF) |
| 157 | Viral load kinetics of Zika virus in plasma, urine and saliva in a couple returning from Martinique, French West Indies | 3.1 | 36 | Citations (PDF) |
| 158 | No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy | 2.5 | 2 | Citations (PDF) |
| 159 | Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection | 3.1 | 50 | Citations (PDF) |
| 160 | Hepatitis E in Transplantation | 2.7 | 16 | Citations (PDF) |
| 161 | Conventional and innate lymphocytes response at the acute phase of HEV infection in transplanted patients | 2.9 | 31 | Citations (PDF) |
| 162 | Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy | 4.2 | 70 | Citations (PDF) |
| 163 | Hepatitis E Virus–Induced Cryoglobulinemic Glomerulonephritis in a Nonimmunocompromised Person | 1.4 | 72 | Citations (PDF) |
| 164 | High Proportion of Asymptomatic Infections in an Outbreak of Hepatitis E Associated With a Spit-Roasted Piglet, France, 2013 | 5.4 | 102 | Citations (PDF) |
| 165 | Proposed reference sequences for hepatitis E virus subtypes | 3.3 | 360 | Citations (PDF) |
| 166 | Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism | 3.5 | 9 | Citations (PDF) |
| 167 | Outcome of Hepatitis E Virus Infection in Patients With Inflammatory Arthritides Treated With Immunosuppressants | 1.3 | 56 | Citations (PDF) |
| 168 | An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients | 1.2 | 63 | Citations (PDF) |
| 169 | Wildlife Reservoir for Hepatitis E Virus, Southwestern France | 3.9 | 43 | Citations (PDF) |
| 170 | HIV-1 Tat Protein Induces Production of Proinflammatory Cytokines by Human Dendritic Cells and Monocytes/Macrophages through Engagement of TLR4-MD2-CD14 Complex and Activation of NF-κB Pathway | 2.4 | 87 | Citations (PDF) |
| 171 | Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates | 1.7 | 5 | Citations (PDF) |
| 172 | Four days a week or less on appropriate anti‐HIV drug combinations provided long‐term optimal maintenance in 94 patients: the ICCARRE project | 0.7 | 22 | Citations (PDF) |
| 173 | Hepatitis E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and southwest France | 3.1 | 66 | Citations (PDF) |
| 174 | Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients | 3.8 | 14 | Citations (PDF) |
| 175 | Traitement de l’infection par le virus de l’hépatite E | 2.7 | 1 | Citations (PDF) |
| 176 | Le virus de l’hépatite E | 2.7 | 3 | Citations (PDF) |
| 177 | Virological failure of patients on maraviroc-based antiretroviral therapy | 3.2 | 9 | Citations (PDF) |
| 178 | Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients | 3.1 | 6 | Citations (PDF) |
| 179 | Temporal evolution of the distribution of hepatitis E virus genotypes in Southwestern France | 2.4 | 34 | Citations (PDF) |
| 180 | Intra-host viral variability in children clinically infected with H1N1 (2009) pandemic influenza | 2.4 | 8 | Citations (PDF) |
| 181 | Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation | 2.1 | 22 | Citations (PDF) |
| 182 | High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study | 5.4 | 14 | Citations (PDF) |
| 183 | Performance of a new rapid test for detecting anti-hepatitis E virus immunoglobulin M in immunocompetent and immunocompromised patients | 3.1 | 23 | Citations (PDF) |
| 184 | Protracted Fecal Shedding of HEV During Ribavirin Therapy Predicts Treatment Relapse | 5.4 | 69 | Citations (PDF) |
| 185 | Hepatitis E virus: Chronic infection, extra-hepatic manifestations, and treatment | 1.9 | 90 | Citations (PDF) |
| 186 | Variability and pathogenicity of hepatitis E virus genotype 3 variants | 3.3 | 55 | Citations (PDF) |
| 187 | An Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-Transplant Recipients | 1.7 | 7 | Citations (PDF) |
| 188 | Virological Diagnosis of Central Nervous System Infections by Use of PCR Coupled with Mass Spectrometry Analysis of Cerebrospinal Fluid Samples | 4.1 | 22 | Citations (PDF) |
| 189 | Influence of Polyproline Region and Macro Domain Genetic Heterogeneity on HEV Persistence in Immunocompromised Patients | 3.8 | 59 | Citations (PDF) |
| 190 | Chikungunya in the Caribbean—Threat for Europe | 3.9 | 9 | Citations (PDF) |
| 191 | Hepatitis E Virus Infections in Blood Donors, France | 3.9 | 128 | Citations (PDF) |
| 192 | Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy | 3.2 | 18 | Citations (PDF) |
| 193 | Hepatitis E in Developed Countries: Current Status and Future Perspectives | 2.1 | 55 | Citations (PDF) |
| 194 | HIV-1 Tat Protein Induces PD-L1 (B7-H1) Expression on Dendritic Cells through Tumor Necrosis Factor Alpha- and Toll-Like Receptor 4-Mediated Mechanisms | 3.7 | 53 | Citations (PDF) |
| 195 | Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients | 43.7 | 482 | Citations (PDF) |
| 196 | Hepatitis E Virus Infection | 17.4 | 574 | Citations (PDF) |
| 197 | Safety measures to prevent hepatitis <scp>E</scp> virus transmission by blood transfusion | 0.8 | 4 | Citations (PDF) |
| 198 | Characterization of the Polyproline Region of the Hepatitis E Virus in Immunocompromised Patients | 3.7 | 65 | Citations (PDF) |
| 199 | Hepatitis E Virus Reinfections in Solid-Organ-Transplant Recipients Can Evolve Into Chronic Infections | 3.8 | 154 | Citations (PDF) |
| 200 | An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing | 1.7 | 31 | Citations (PDF) |
| 201 | Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection | 3.6 | 10 | Citations (PDF) |
| 202 | Chronic Hepatitis E Virus Infection and Treatment | 2.5 | 69 | Citations (PDF) |
| 203 | Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients | 3.1 | 114 | Citations (PDF) |
| 204 | Risk of zoonotic transmission of HEV from rabbits | 3.1 | 60 | Citations (PDF) |
| 205 | Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence | 3.2 | 10 | Citations (PDF) |
| 206 | Evaluation of a polymerase chain reaction–electrospray ionization time-of-flight mass spectrometry for the detection and subtyping of influenza viruses in respiratory specimens | 3.1 | 17 | Citations (PDF) |
| 207 | Hepatitis C virus and kidney disease | 1.9 | 17 | Citations (PDF) |
| 208 | Hepatitis E virus infection | 2.3 | 37 | Citations (PDF) |
| 209 | Characterization of CXCR4-using HIV-1 during primary infection by ultra-deep pyrosequencing | 3.2 | 13 | Citations (PDF) |
| 210 | Genotypic Prediction of HIV-1 CRF01-AE Tropism | 4.1 | 34 | Citations (PDF) |
| 211 | National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011 | 3.2 | 43 | Citations (PDF) |
| 212 | Hepatitis E Virus Infection in Immunosuppressed Patients: Natural History and Therapy | 3.4 | 90 | Citations (PDF) |
| 213 | An Analysis of the Benefit of Using HEV Genotype 3 Antigens in Detecting Anti-HEV IgG in a European Population | 2.4 | 56 | Citations (PDF) |
| 214 | Hepatitis E Virus Quasispecies and the Outcome of Acute Hepatitis E in Solid-Organ Transplant Patients | 3.7 | 102 | Citations (PDF) |
| 215 | Phenotyping methods for determining HIV tropism and applications in clinical settings | 3.3 | 18 | Citations (PDF) |
| 216 | Presence of Lamivudine or Emtricitabine Is Associated with Reduced Emergence of Nonnucleoside Reverse Transcriptase Inhibitor Mutations in an Efavirenz-Based Intermittent Antiretroviral Treatment Regimen | 4.2 | 9 | Citations (PDF) |
| 217 | Genotype 3 Diversity and Quantification of Hepatitis E Virus RNA | 4.1 | 118 | Citations (PDF) |
| 218 | Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients | 1.2 | 186 | Citations (PDF) |
| 219 | Antiviral Effect of Maraviroc in Semen: A Case Report | 2.1 | 8 | Citations (PDF) |
| 220 | Hepatitis E | 52.8 | 899 | Citations (PDF) |
| 221 | Performance of a rapid molecular multiplex assay for the detection of influenza and picornaviruses | 1.6 | 9 | Citations (PDF) |
| 222 | Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation | 3.1 | 58 | Citations (PDF) |
| 223 | HIV-1 Tropism and Liver Fibrosis in HIV–HCV Co-Infected Patients | 2.4 | 5 | Citations (PDF) |
| 224 | Hepatitis E Virus Strains in Rabbits and Evidence of a Closely Related Strain in Humans, France | 3.9 | 243 | Citations (PDF) |
| 225 | Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants | 1.0 | 624 | Citations (PDF) |
| 226 | X4 Tropic Multi-Drug Resistant Quasi-Species Detected at the Time of Primary HIV-1 Infection Remain Exclusive or at Least Dominant Far from PHI | 2.4 | 6 | Citations (PDF) |
| 227 | Genotypic prediction of HIV-1 subtype D tropism | 3.6 | 40 | Citations (PDF) |
| 228 | Hepatitis E Virus Infection without Reactivation in Solid-Organ Transplant Recipients, France | 3.9 | 143 | Citations (PDF) |
| 229 | Hepatitis E Virus and Neurologic Disorders | 3.9 | 304 | Citations (PDF) |
| 230 | Hepatitis E Virus Antibodies in Blood Donors, France | 3.9 | 325 | Citations (PDF) |
| 231 | Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism | 3.2 | 14 | Citations (PDF) |
| 232 | Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism | 4.2 | 46 | Citations (PDF) |
| 233 | Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencingAids, 2011, 25, 1668-1670 | 2.5 | 24 | Citations (PDF) |
| 234 | Definitive Clearance of a Chronic Hepatitis E Virus Infection With Ribavirin Treatment | 0.7 | 46 | Citations (PDF) |
| 235 | Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey | 0.8 | 54 | Citations (PDF) |
| 236 | Minor HIV-1 Variants with the K103N Resistance Mutation during Intermittent Efavirenz-Containing Antiretroviral Therapy and Virological Failure | 2.4 | 35 | Citations (PDF) |
| 237 | Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland | 3.9 | 130 | Citations (PDF) |
| 238 | No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients | 2.1 | 55 | Citations (PDF) |
| 239 | Prediction of HIV Type 1 Subtype C Tropism by Genotypic Algorithms Built From Subtype B Viruses | 1.8 | 52 | Citations (PDF) |
| 240 | Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation | 1.2 | 215 | Citations (PDF) |
| 241 | Characteristics of Autochthonous Hepatitis E Virus Infection in Solid‐Organ Transplant Recipients in France | 3.8 | 179 | Citations (PDF) |
| 242 | Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients | 2.6 | 184 | Citations (PDF) |
| 243 | Low Frequency of CXCR4-Using Viruses in Patients at the Time of Primary Non-Subtype-B HIV-1 Infection | 4.1 | 26 | Citations (PDF) |
| 244 | Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial | 3.2 | 47 | Citations (PDF) |
| 245 | Pegylated Interferon‐α for Treating Chronic Hepatitis E Virus Infection after Liver Transplantation | 5.4 | 197 | Citations (PDF) |
| 246 | Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study | 4.2 | 65 | Citations (PDF) |
| 247 | Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient | 0.8 | 100 | Citations (PDF) |
| 248 | Influence of pre-analytical conditions on plasma ribavirin concentrations | 0.8 | 2 | Citations (PDF) |
| 249 | Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection | 1.0 | 279 | Citations (PDF) |
| 250 | Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage | 3.1 | 66 | Citations (PDF) |
| 251 | Hepatitis E virus excretion can be prolonged in patients with hematological malignancies | 3.1 | 127 | Citations (PDF) |
| 252 | Hepatitis C Virus Genotyping Using an Oligonucleotide Microarray Based on the NS5B Sequence | 4.1 | 21 | Citations (PDF) |
| 253 | CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progressionAids, 2010, 24, 2305-2312 | 2.5 | 76 | Citations (PDF) |
| 254 | HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy | 2.4 | 120 | Citations (PDF) |
| 255 | Determining Seminal Plasma Human Immunodeficiency Virus Type 1 Load in the Context of Efficient Highly Active Antiretroviral Therapy | 4.1 | 28 | Citations (PDF) |
| 256 | Good Performance of Immunoglobulin M Assays in Diagnosing Genotype 3 Hepatitis E Virus Infections | 3.0 | 84 | Citations (PDF) |
| 257 | Genotypic Prediction of Human Immunodeficiency Virus Type 1 CRF02-AG Tropism | 4.1 | 48 | Citations (PDF) |
| 258 | Hepatitis E Virus Genotype 3 Diversity, France | 3.9 | 144 | Citations (PDF) |
| 259 | Molecular Evidence of Patient‐to‐Patient Transmission of Hepatitis E Virus in a Hematology Ward | 5.4 | 51 | Citations (PDF) |
| 260 | Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy | 3.8 | 56 | Citations (PDF) |
| 261 | Mathematical modeling of hepatitis C virus transmission in hemodialysis | 2.1 | 15 | Citations (PDF) |
| 262 | High prevalence of anti‐hepatitis E virus antibodies in blood donors from South West France | 3.8 | 166 | Citations (PDF) |
| 263 | Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV | 3.8 | 37 | Citations (PDF) |
| 264 | Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients | 43.7 | 1,296 | Citations (PDF) |
| 265 | Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism | 2.5 | 115 | Citations (PDF) |
| 266 | Population-Based Sequencing of the V3 Region of
env
for Predicting the Coreceptor Usage of Human Immunodeficiency Virus Type 1 Quasispecies | 4.1 | 86 | Citations (PDF) |
| 267 | New Natural Intergenotypic (2/5) Recombinant of Hepatitis C Virus | 3.7 | 105 | Citations (PDF) |
| 268 | Genetic diversity of HCV genotype 2 strains in South Western France | 3.8 | 24 | Citations (PDF) |
| 269 | Determining the source of nosocomial transmission in hemodialysis units in Tunisia by sequencing NS5B and E2 sequences of HCV | 3.8 | 17 | Citations (PDF) |
| 270 | Prolonged hepatitis E in an immunocompromised patient | 2.7 | 76 | Citations (PDF) |
| 271 | Hepatitis E is an autochthonous disease in industrialized countries | 1.0 | 65 | Citations (PDF) |
| 272 | Validation of an automated real-time PCR protocol for detection and quantitation of HIV and HCV genomes in semen | 1.7 | 16 | Citations (PDF) |
| 273 | Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance | 3.8 | 56 | Citations (PDF) |
| 274 | Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon | 3.8 | 14 | Citations (PDF) |
| 275 | Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient | 1.4 | 58 | Citations (PDF) |
| 276 | Natural History of Hepatitis C Virus-Related Liver Fibrosis After Renal Transplantation | 4.6 | 119 | Citations (PDF) |
| 277 | Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C | 3.8 | 28 | Citations (PDF) |
| 278 | Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection | 3.8 | 50 | Citations (PDF) |
| 279 | Incidence of HCV infection in French hemodialysis units: A prospective study | 3.8 | 75 | Citations (PDF) |
| 280 | R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy | 1.8 | 107 | Citations (PDF) |
| 281 | Convenient Biological Assay for Polyethylene Glycol-Interferons in Patients with Hepatitis C | 4.2 | 6 | Citations (PDF) |
| 282 | Immunologically Silent Autochthonous Acute Hepatitis E Virus Infection in France | 4.1 | 47 | Citations (PDF) |
| 283 | Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes | 2.5 | 80 | Citations (PDF) |
| 284 | Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function | 1.4 | 77 | Citations (PDF) |
| 285 | Hepatitis E in the south west of France in individuals who have never visited an endemic area | 3.8 | 233 | Citations (PDF) |
| 286 | Evidence that Clearance of Hepatitis C Virus RNA after α-Interferon Therapy in Dialysis Patients Is Sustained after Renal Transplantation | 0.4 | 174 | Citations (PDF) |
| 287 | Genetic Heterogeneity of the NS5A Gene of Hepatitis C Virus and Early Response to Interferon‐α | 3.8 | 9 | Citations (PDF) |
| 288 | Evolution of Total and Integrated HIV-1 DNA and Change in DNA Sequences in Patients with Sustained Plasma Virus Suppression | 2.3 | 30 | Citations (PDF) |
| 289 | Low-Rate Emergence of Thymidine Analogue Mutations and Multi-Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Gene in Therapy-Naive Patients Receiving Stavudine plus Lamivudine Combination Therapy | 2.1 | 27 | Citations (PDF) |
| 290 | Hepatitis C virus infection in French hemodialysis units: A multicenter study | 3.8 | 73 | Citations (PDF) |
| 291 | A pharmacokinetic model for alpha interferon administered subcutaneously | 2.7 | 47 | Citations (PDF) |
| 292 | Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit | 3.8 | 85 | Citations (PDF) |
| 293 | TREATMENT OF CHRONIC HEPATITIS C WITH RECOMBINANT INTERFERON ALPHA IN KIDNEY TRANSPLANT RECIPIENTS | 1.2 | 189 | Citations (PDF) |
